ACCENTRIX 10MGML SOLUTION FOR INJECTION

国家: 马来西亚

语言: 英文

来源: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

现在购买

下载 资料单张 (PIL)
18-04-2017
下载 产品特点 (SPC)
25-10-2022

有效成分:

Ranibizumab

可用日期:

NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.

INN(国际名称):

Ranibizumab

每包单位数:

1Units Units

厂商:

NOVARTIS PHARMA STEIN AG

资料单张

                                Not Applicable
                                
                                阅读完整的文件
                                
                            

产品特点

                                Novartis
Page 2
Malaysian Package Leaflet
28-Feb-2022
Accentrix
ACCENTRIX

Antineovascularization agents
DESCRIPTION AND COMPOSITION
PHARMACEUTICAL FORM
Solution for injection.
Accentrix is supplied in a vial.
Sterile, clear, colorless to pale yellow and preservative-free aqueous
solution.
ACTIVE SUBSTANCE
One mL contains 10 mg ranibizumab.
Each vial contains 2.3 mg of ranibizumab in 0.23 mL solution.
Ranibizumab is a humanized monoclonal antibody fragment produced in
_Escherichia coli _
cells
by recombinant DNA technology.
EXCIPIENTS
alpha, alpha-trehalose dihydrate, histidine hydrochloride,
monohydrate, histidine, polysorbate
20, water for injections.
INDICATIONS
Accentrix is indicated in adults for:
•
The treatment of neovascular (wet) age-related macular degeneration
(AMD)
•
The treatment of visual impairment due to diabetic macular oedema
(DME)
•
The treatment of proliferative diabetic retinopathy (PDR)
•
The treatment of visual impairment due to macular oedema secondary to
retinal vein
occlusion (RVO)
•
The treatment of visual impairment due to choroidal neovascularization
(CNV)
Accentrix is indicated in preterm infants for:
•
The treatment of retinopathy of prematurity (ROP) with zone I (stage
1+, 2+, 3 or 3+), zone
II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
Novartis
Page 3
Malaysian Package Leaflet
28-Feb-2022
Accentrix
DOSAGE REGIMEN AND ADMINISTRATION
DOSAGE REGIMEN
Single-use vial (adults and preterm infants) for intravitreal use
only. Use of more than one
injection from a vial can lead to product contamination and subsequent
ocular infection.
Accentrix must be administered by a qualified ophthalmologist
experienced in intravitreal
injections.
POSOLOGY
_ADULTS _
The recommended dose for Accentrix in adults is 0.5 mg given as a
single intravitreal injection.
This corresponds to an injection volume of 0.05 ml. The interval
between two doses injected
into the same eye should be at least four weeks.
Treatment in adults is initiated with one injection per month until
maximum 
                                
                                阅读完整的文件
                                
                            

搜索与此产品相关的警报